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INTRODUCTION 
 
 
Acute myeloid leukemia is a clonal hematopoietic disorder which may 
be derived from either lineage specific progenitor cell or a hematopoietic 
stem cell. 
 It is characterized both by a predominance of immature or mature 
forms of white blood cells and loss of normal hematopoiesis. It usually 
presents with leukocytosis or leukopenia with anemia and 
thrombocytopenia.(1) 
Epidemiology and Pathogenesis 
 Deschler et al in his studies in 2006 found the age-adjusted 
incidence of AML around 3.4 cases per 100,000 persons. AML can 
occur in patients of any age, but in general studies have shown that the 
overall incidence and the proportion of acute myeloid leukemias increase 
with age.  
 When childhood AML is considered, Gurney et al in his studies 
found maximum incidence occurs in the first year of life, and then 
decreases until age 4, and there after relatively remains constant until 
adult age group when it again starts to increase.  
2 
 
 Approximately 70% of acute leukemias in adults are AML, with a 
marked increase in incidence in the elderly. The increase is due to AML 
with MDS-related changes in marrow, which is more common with age, 
while the in the case of incidence of de novo AML, it remains almost 
same. 
Indian & MMTR Data 
 As per Madras metropolitian cancer registry, incidence of acute 
leukemia is rising trend (2, 3). In 1984-88 it constituted 4.0% of total 
cancer patients. But in 2008 -2010 data, its incidence is increasing and 
now constitutes almost 6.9% of all cancer burdens (3).  Acute myeloid 
leukemia constitutes the major burden of leukemia in patients with age 
more than 15 years. 
Risk Factors for AML 
 Congenital diseases 
Down syndrome, Severe congenital Neutropenia,  Dyskeratosis 
Congenita, Fanconi anemia 
 Environmental Exposures-  
Ionizing radiation, Benzene exposure, Cigarette smoking 
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 Chemotherapy 
Topoisomerase II Inhibitors, Alkylating chemotherapy, Anthracyclines , 
Anti-tubulin agents  
 Denovo AML  
Classification of AML (WHO 2008) (4) 
 Acute myeloid leukemia with  Genetic abnormalities 
                   AML with t (8; 21) (q22;q22); RUNX1 
                  AML with inv (16) CBFB-MYH11 
                  APL with t (15; 17); PML-RARA 
                  AML with t (9; 11); MLLT3-MLL 
 Acute myeloid leukemia with Myelodysplasia-related changes 
 Therapy-related myeloid neoplasm 
 Acute myeloid leukemia, not otherwise Speciﬁed 
 
Risk stratification of AML (5) 
Acute Myeloid leukemia is presently risk stratified on basis of 
cytogenetic and molecular Abnormality and response to induction 
therapy. 
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Good Risk Intermediate Risk Poor Risk 
CEBP2A double mutated Normal karyotype+ 
FLT3-,NPM1 - 
Monosomy 7 
Core binding 
factor(CBF) gene 
Associated AML 
 
t (8:21) translocation 
inversion 16 
Numerical Abberation 
-Y 
+8 
+11 
+13 
Complex abnormality 
 (>-3 chromosomal    
abnormalty) 
Normal karyoype with 
FLT3- , NPM1 + 
t (9:11),trisomy 8 t(9:22) 
t (15 :17),PML RARA+ Del 7q 
Del 9q 
Any Karyotype with 
FLT3 ITD +ve 
Treatment approach for acute myeloid leukemia 
 Fit patients (< 60-65 years, select patients up to age 75 y) are 
candidates of intensive therapy. Treatment includes induction therapy 
and Consolidation therapy. High risk-patients are evaluated for stem cell 
transplantation at first remission. 
Less fit patients (60-75 years and older, or younger patients with 
significant comorbidities) receive low-intensity therapy. (1) 
Treatment recommendations for fit AML patients < 60y or for select 
patients ≤ 75y (good performance status, minimal co morbidities) 
1. Induction therapy: 
Combination of cytarabine and anthracycline is recommended 
[5, 6, 7, 8,] 
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Cytarabine 100-200 mg/m
2
 continuous IV infusion for 7d   plus 
Daunorubicin 60-90 mg/m
2
/day for 3d 
Follow-up bone marrow to assess remission is typically done 21-28d 
after completion of induction chemotherapy 
2. Post remission therapy (consolidation) (
9, 10,11,12, 13, 14, 15, 16, 17, 18, 19,20
 ) 
 All patients should be assessed for risk of relapse. Specific drug 
regimens are recommended based on a patient’s risk of relapse. 
Good-Risk patients: 
 High-dose cytarabine 3 g/m
2
 IV over 3h every 12h on days 1, 3, 
and 5 for 3 cycles 
 
or  
 Intermediate dose cytarabine 1.5gm/m2 over 3 hrs every 12 h on 
Day 1, 3, and 5 for 3 cycles 
Intermediate-risk patients: 
 High-dose/ Intermediate dose Ara C (1.5gm/3.0 g/m
2
 IV) for 3 
cycles or Allogeneic bone marrow transplantation 
High-risk patients: 
 Allogeneic stem cell transplantation or 
 Clinical trial or 
 High-dose/intermediate dose cytarabine (1.5gm/3.0 g/m) IV over 
3h every 12h on days 1, 3, and 5  
Acute ProMyelocytic leukemia (APML) is disease with different 
biology, treated differently with a separate protocol.  
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REVIEW OF LITERATURE 
 
 
Hematopoietic growth factors & its role in the treatment of acute 
myeloid leukemia 
 The treatment outcomes in AML have significantly improved in 
the last 2 decades with large number of patients achieving long term 
disease free survival. One of the major factors contributing to 
improvement in survival in these patients is improvement in supportive 
care during therapy. 
 Over the last 2-3 decades, though little has changed in terms of the 
chemotherapeutic drugs used in induction and consolidation therapy, 
notable improvements in intensive care, antibiotic use, growth factor 
support and antifungal use have all contributed to improvements 
 Growth factors are usually given to AML patients following 
completion of chemotherapy, with the goal of attenuating hematologic 
toxicity. They might help to reduce the duration of neutropenic period 
and the depth of neutropenia, thus helping to decrease the incidence of 
febrile infective episodes the duration of hospital stay and cost.   This 
beneficial effect decrease incidence of febrile infective episodes, the 
duration of hospital stay and cost.   
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 Studies have shown G CSF to have major impact on attenuating 
morbidity of AML patients undergoing chemotherapy, but have not 
shown to improve survival. (21, 22) 
Growth Factors After Induction Therapy 
 The Published literature shows mixed results with respect to the 
benefits of use of growth factors during the remission-induction therapy 
of AML.   
 These trials differ from each other with respect to a number of 
factors like choice of growth factor, patient age and comorbidities, stage 
of disease and dchemotherapy regimen, including agents and doses used. 
  A randomized trial was done by Ohno et al (21) done on G CSF 
administration following AML chemotherapy. Patients with relapsed or 
refractory leukemia were the study group. They were randomized to 
receive Growth factors at a daily dose of 200 µg/m or placebo, beginning 
after completion of Etoposide,mitoxantrone,cyarabine chemotherapy, 
until absolute neutrophil counts reached 1.5 x 109/L. 
 Neutrophil recovery was seen to be more rapid in 48 patients who 
received G-CSF than in 50 patients who did not; which was statistically 
significant. Median days to neutrophil recovery of 1.0 x 109/L 
neutrophils was 22 days v 34 days in corresponding groups (P = .0002). 
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 Toxicity was almost similar in both groups, with fever being 
predominant complication. Infective episodes were significantly less  in 
patients who received G-CSF (P = .028) & the  Complete remission rates 
were 50% in GCSF v 36% in placebo group.This difference was not 
statistically significant. The incidence of early relapse, sustain remission 
& survival was not different in both groups which were major concern at 
that time. 
 In study by Buchner et al (22)   treated 25 newly diagnosed elderly 
AML patients > 65 years of age, as well as in early relapse, with G-CSF  
administered  b  after completion of Daunorubicin, cytarabine, 6 Thio 
guanine or high-dose cytarabine (HIDAC) and mitoxantrone 
chemotherapy. 
 He also found Neutrophil recovery was earlier  in patients who 
received the G CSF after either chemotherapy  regimen, compared to 
historical group (P = .009 and .043 for the two groups,). Differences in 
median time to neutrophil recovery were 6 and 9 days for the two 
regimens respectively. 
 Further results showed Mortality was lower in GCSF arm (14% vs 
39%). Complete remission rates were also more in GCSF arm (50% vs 
32%) (P =.09), and there was no increased relapse in growth factor arm 
with equal duration remission. (22, 23) 
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 Rowe et al from Eastern Cooperative Oncology Group (ECOG)  
reported role of GCSF (24) in 124 newly diagnosed elderly AML 
patients (Age >65 years) who  received cytarabine 100 mg/m2  by 
continuous infusion and daunorubicin 60 mg/m2 daily for 3 days. They 
randomized patients to receive G-CSF 250 µg/d or placebo.  
 Results showed that G-CSF had a statistically significant, 
favorable effect on neutrophil recovery of 0.5 x 10 9/L , ie ANC >500 
(11 days v 14 days , P = .01) and 1.0 x10 9/L neutrophils, ie ANC 
>1000(12 days v 18 days,  P = .001), It also reduced the incidence of 
infectious toxicity compared to observational arm. (24% on the G-CSF 
arm v 32% on the placebo,  P =.019). 
 The Complete remission rates were 61% for patients treated in the 
growth factor arm and 46% for those who received placebo. Median 
survival was 325 days v 135 days in corresponding groups (P = .035) 
which was statistically significant. The higher incidence of toxic death in 
placebo arm was the major cause of decreased survival in these patients. 
 One of the negative studies on role of growth factors was the 
Cancer and Leukemia Group B (CALGB) study (25).  It had 388 new 
patients of AML>60 years age ,and  were randomized to receive G-CSF 
or placebo after induction treatment, which had Ara c 200 mg/m2 for 7 
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days and daunorubicin 45 mg/m2  for 3 days. GCSF was continued until 
neutrophil recovery of 1.0 x 109/L .  
 Results showed no significant difference in duration of 
neutropenia observed between the two groups (16 days v 17 days for 
placebo).  No differences were noted in rates of infectious complication 
or remission status also. 
 The ECOG trial and CALGB studies have contradictory results 
even after large number patients. The main reason was both have used 
separate regimen. The higher anthracycline dose in the ECOG study 
would have resulted in a longer duration of neutropenia compared to the 
CALGB regimen which was milder. This longer neutropenia would have 
been alleviated by G-CSF in ECOG study. Studies have now clearly 
shown that dose of Anthracycline is important in determining outcome 
of AML patients.   (22) 
 Roswell Park Institute conducted a pilot study to determine 
whether G-CSF could attenuate the hematologic toxicity associated with 
intensive HDAC and anthracycline induction chemotherapy. (26) GCSF 
was administered to all patient at dose of 250mcg/day and was continued 
until the absolute neutrophil count rose to ANC >5000 on 2 consecutive 
days. 
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 Results showed remission rate with a single course of induction 
therapy was 75% and 10% induction mortality. Remission had occurred 
in 86% of patients < 60 years and 65% of those >= 60 years of age. G 
CSF helped in faster neutrophil recovey. Mortality rate was similar in the 
two age groups (9% and 10%). So it was concluded that GCSF 
administered in induction hasten neutophil recovery and decreases 
complication. 
Results of Various studies on G CSF in AML induction 
 
Study Population Phase Outcome Comments 
Ohio et al Elderly 
(>65yrs) 
RCT 
Induction Faster ANC 
Recovery(22v34) 
No risk of 
increased 
relapse . 
Buschner 
et al 
Elderly/ 
Relapse 
AML 
Induction Faster ANC 
recovery 
(8v11days) 
No risk of 
inceased 
relapse 
ECOG Elderly 
AML RCT 
induction Faster ANC 
recovery 
(11v14days) 
Decreased 
mortality in 
GCSF 
CALGB Elderly 
(>65y) RCT 
induction Equal days of 
recovery. No 
added benefit of 
GCSF 
Negative 
study 
Roswell 
Park 
Cancer 
institute 
 
All Age 
groups (pilot 
study) 
Induction Faster ANC 
recovery 
No increased 
risk of 
relapse 
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Controversies of GCSF in AML Induction (27) 
 There has been great concern that growth factors given to AML 
patients to promote the growth of residual leukemic cells and thereby 
increasing the rate of induction failure or early relapse.  
 Although data are still limited, studies published to date support 
the conclusion that G-CSF administered to AML patients after induction 
chemotherapy, with effective cytoreduction, do not increase the risk of 
remission induction failure due to persistent leukemia, rapid re growth of 
leukemia cells, or relapse rate. 
 So at present GCSF administration during AML induction 
chemotherapy is still a topic of debate, but it is used widely in elderly 
patients and unfit patients undergoing AML induction to attenuate 
toxicities. 
Guidelines on use of Growth Factor use in cancer 
 ESMO recommends primary prophylaxis with growth factors for a 
chemotherapy with a risk of febrile neutropenia >20%.Therapy of Acute 
leukemia & stem cell transplantation lead to higher risk of febrile 
neutropenia & potentially lethal complications; so it recommends both G 
CSF and peg GCSF in these situations(28). 
NCCN also recommends prophylactic growth factors for chemotherapy 
with risk of febrile neutropenia>20% &chance of lethal complications 
(29). 
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Evolution of Consolidation Chemotherapy in AML (30, 31 ,32) 
 According to L1210 leukemia model, Post induction marrow 
leukemic blasts has 3 log reduction. Further consolidation chemotherapy 
has shown to bring down blasts to undetectable state. So consolidation 
chemotherapy is considered standard in acute leukemia. In AML 
consolidation is given by high dose Cytarabine based chemotherapy. 
 There is substantial evidence to demonstrate that intensive 
consolidation therapy in AML patients who achieve complete remission 
improves remission duration and helps the patients to achieve long-term, 
disease-free survival. Therapeutic approaches include high-dose or 
intermediate dose cytarabine chemotherapy. (30, 31) 
 Evolution of modern Consolidation chemotherapy with Single 
agent high dose cytarabine arabinoside in AML has mainly been based 
on the Cancer and Leukemia Group B (CALGB) 8525 trial, which 
included patients of all age group. All received standard induction with 3 
+7 chemotherapy .They were randomly allocated at remission to four 
cycles of cytarabine at various doses (100 mg/m2 , 400 mg/m2 &  3 
gm/m2 given on days 1, 3, and 5 ). 
 At the end of analysis it was seen that patients who were  allocated 
to the high-dose ara-C arm experienced a superior EFS & OS (overall 
survival) compared with those allocated to lower doses of ara-C.This 
was significant for age <60 yrs of patients (30). 
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 Subgroup analysis of this work demonstrated that the beneﬁt of 
high-dose cytarabine was mainly in those patients with so-called 
favorable chromosomal abnormalities at diagnosis ie Core binding factor 
leukemias (inv 16 and t (8; 21)). 
 Other conclusion was, this is a toxic and expensive regimen with a 
low but appreciable rate of treatment-related mortality. To prevent the 
toxic death supportive care in the form of growth factor became the 
practice. Second, even among the most good risk arm only about two 
thirds are cured; patients with high risk disease biology are rarely cured. 
There have been several efforts to improve on high-dose ara-C post 
remission therapy in form of adding autologous transplant but was not 
found fruitful.  
 On trying to improve outcome further, German Study Alliance 
Leukemia (SAL group) studied on patients post induction receiving 
consolidation with either high dose ara c for 3 cycles or multi agent 
consolidation with mitoxantrone/Amsacrine added to Ara C. According 
to final analysis, the multi agent consolidation did not prove beneﬁt with 
regard to disease-free or overall survival.  
 Recently completed M RC AML15 Trial which studied patients 
with acute myeloid leukemia has compared 3.0gm/m2 dose of cytarabine 
15 
 
and 1.5gm/m2 of cytarabine used in AML consolidation & has found to 
have equivalent outcome. (32) 
 So three cycles of Intermediate / high dose cytarabine 
chemotherapy has become standard approach in Acute Myeloid 
Leukemia patients post induction as consolidation chemotherapy. 
Growth Factors After Consolidation Therapy 
 Problems with  strategy of single agent cytarabine arabinoside 
consolidation protocol treatment  is that patient have severe 
myelosupression for approximately 3 weeks post treatment and there is 
high chance of significant morbidity and mortality during this time. 
Various Attempts has been done to attenuate this issue. It includes 
lowering the dose of cytarabine, starting on Growth factors, and early 
initiation on Antibiotics, improved blood products transfusion etc. Out of 
which addition of G CSF has made a major impact on outcome of these 
patients. 
 Several randomized trials have analyzed whether Growth factors 
can reduce the duration of neutropenia in AML patients during 
consolidation phase without compromising the clinical outcome. (33) 
and they showed that the use of GCSF significantly shortened the 
duration of  neutropenia, which also reduced the need for hospitalization 
and  antibiotic use. (30-31) 
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 Published data from a large randomized,  placebo- controlled, 
phase III study of filgrastim in remission induction and consolidation 
therapy for adults with de novo acute myeloid leukemia.(33) The results 
has confirmed on the safety and efficacy of G CSF in reducing the 
morbidity associated with AML treatment. It showed that it hastened 
neutrophil recovery and after a median follow up of 7 yrs there was no 
difference in DFS/OS and no increased risk of relapse. 
 In an Eastern Cooperative Oncology Group (ECOG) study  
reported by Rowe et al (24) of  124 newly diagnosed AML patients ,who 
was in post induction remission,  Growth factor or placebo was 
administered following consolidation, which consisted of a single course 
of high-dose cytarabine (1.5 g/m2) .  
 G-CSF had a significant, favorable effect on neutrophil recovery 
of 0.5 x 10 9/L (11 days   vs 14 days   P = .01) and 1.0 x10 9/L 
neutrophils (12 days v 18 days,P = .001).There was well less  incidence 
of infectious toxicity in GCS arm (24% v 32% in placebo ; P 
=.019).There was no major difference in incidence of relapse in both 
groups on long term follow up. 
 In another phase 3 study of G CSF in consolidation patient of 
AML (International AML study group) there was statistically significant 
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decrease in morbidity,febrile complications,  incidence of neutropenia,  
and early neutrophil recovery in GCSF subsets (34). The toxicity profile 
was also not increased in GCSF subsets nor was relapse rate. 
 Lowenberg et al in his study evaluated the Quality of Life and 
effects of GCSF patients for remission induction and consolidation phase 
of AML therapy. It has also shown to decrease median duration of 
neutropenia with preserved good quality of life and favourable toxicity 
profile. No difference was seen in overall survival of these subsets. (35) 
 There are two studies with use of recombinant growth factors in 
AML patients during induction & consolidation and have even 
demonstrated an increase in complete remission (CR) rate and Overall 
Survival (36,37,38). These are the only studies which have shown 
overall survival benefit with use of growth factors. But others did not 
confirm these results. 
 
Various studies on Role of G CSF in AML Consolidation 
Study Phase Outcome Comments 
Heil et al Consolidation 
RCT 
Faster ANC 
recovery + less 
infection 
Decreased 
mobidity.No 
increased 
relapse 
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Lowenberg et 
al 
 
Consolidation 
RCT 
Faster ANC 
recovery 
Improved QOL  
in GCSF. No 
change in 
mortality 
Rowe et al 
ECOG 
Consolidation 
RCT 
Faster ANC 
recovery + less 
infection 
Decreased 
morbidity & 
sustained 
remission. 
International 
AML study 
group 
Consolidation Faster ANC 
recovery + less 
infection 
Favourable 
toxicity profile 
+ no increase 
relapse 
 
 In Conclusion use of G CSF is safe and now routine on all AML 
patients undergoing Post remission Consolidation chemotherapy. It has 
definitely shown to reduce the duration of severe neutropenia, fastens the 
neutrophil recovery, decrease febrile complications and thereby 
decreasing morbidity in these subsets. The impact of these in overall 
survival of patients in AML requires further studies. 
Other uses of GCSF proposed in AML patients  
 There have been studies on priming of leukemic cells with growth 
factors in AML, before the start of chemotherapy for more effective cell 
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kill, but it has not produced satisfactory results and cannot be 
recommended at present as standard of care.(39) 
Growth Factors have been also now routinely used in Mobilization of 
stem cells during harvest for Donor of AML patient undergoing Bone 
marrow Transplant. (40) 
Pegylated G CSF 
Peg filgrastim is a recent introduction to the family of growth factors. It 
is a 38,000 Da, Pegylated variant of recombinant human granulocyte 
colony-stimulating factor (G-CSF).  Since G CSF is produced in E. coli 
cells, the molecule is non-glycosylated and therefore, differs from G-
CSF isolated from a human cell.  Pegfilgrastim is made by attaching a 
polyethylene glycol (PEG) to filgrastim.(40) 
 
      Conventional GCSF                PEG GCSF 
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Pharmacokinetics 
 Single dose of pegylated growth factor when injected 
subcutaneously,the peak serum   concentration occurs upto 16-120 hours 
,and studies have found it is maintained during the whole course of 
neutropenia after myelosupressive chemotherapy. (41) 
 The elimination of peg filgrastim is not linear with respect to dose, 
serum clearance decrease with increasing dose. The major advantage of 
pegylated filgrastim is its neutrophil mediated clearance. Serum level of 
peg gcsf has been shown to decline rapidly after onset of neutrophil 
recovery. (42) 
 
Dose 
Standard Adult dose >40kg, is 6.0mg subcutaneous-single dose 
Studies in children has used dose 100mcg/kg s/c –single dose 
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Side effect profile 
 Trials done have showed it is safe in patients, and toxicity is 
comparable to conventional GCSF.  
Most common side effect seen with pegylated GCSF is  
1. Bone pains 
2. Myalgia  
3.  Fatigue.  
 Mainly calf, thigh and lower back are most common sites of pain. 
Studies have shown up to 40-50% of patients having grade1 of these side 
effects. But severe toxicities are very rare. 
 Studies in children has reported mild headache. Some patients also 
had increased incidence of pedal edema.  
 Other less common side effects include Flu like illness, Pain at 
injection site, Anaphylaxis or hyper sensitivity reactions. 
Rarely reported cases of Acute respiratory distress syndrome (ARDS) 
and capillary leak syndrome.  
 Very rarely fatal splenic rupture has also been reported in patients. 
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Pegylated growth factors in Cancer Chemotherapy 
 Various trials have been done about role of Peg GCSF in both 
solid tumours and lymphoma, to fasten neutrophil recovery and decrease 
incidence of neutropenia. This has shown to decrease morbidity. 
 Regimens with an overall risk of febrile neutropenia of ≥20% have 
been advised to be started on prophylactic Growth factors. These include 
regimens that are used for treatment of Breast cancer like TAC, CHOP-
like regimens used for Non-Hodgkin’s lymphoma and the DCF/TPF 
regimen used for head &neck and gastric cancers etc.  
 A meta-analysis of five different studies in a total of 600 patients 
treated for lymphoma or breast cancer showed that a single dose of peg 
GCSF 6.0mg was significantly more effective than 10–14 days of  
multiple G CSF in reducing infective episodes (43, 44).   
 Larger meta-analysis data by Kuderer et al. (45) also suggest that 
peg GCSF was more effective than GCSF, and that also with a 
favourable toxicity profile. Analysis found that in   patients receiving 
various chemotherapy regimens (total of 15,763 cycles), the risk of 
hospitalisation was approximately 30% lower with peg GCSF support 
than with daily G-CSF (45). 
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 These datas clearly shown that, Pegylated GCSF has shown its 
non inferiority,ease of administration and favourable toxicity profile 
compared to conventional G CSF  in  patients with cancer undergoing 
various chemotherapy  
Pegylated growth factors in pediatric population 
 Data on role of Peg GCSF safety and efficacy in children at 
present are scanty but upcoming. 
 Cesaro et al has studied role of single dose of 100 mcg/kg peg G 
CSF in mobilizing peripheral blood stem cells (PBSCs) in pediatric 
patients undergoing autologous stem cell transplant.The results on 36 
children showed it to be equally efficacious with favourable toxicity 
profile (47). 
 Peg filgrastim was studied for chemotherapy associated 
neutropenia in children with solid tumors. Median age was 6 yrs (1-20 
yrs).They concluded that Peg GCSF following chemotherapy for solid 
tumors is feasible in children. The duration of  neutropenia,  incidence of 
febrile neutropenia, were similar to GCSF historic data. It did not have 
any added toxicity (48). 
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Pegylated growth factors AML Consolidation 
 Acute Myeloid leukemia patients are most of time neutropenic 
before start of chemotherapy. Before starting consolidation 
chemotherapy also they are at times infected or would have recovered 
from major induction chemotherapy. More over further consolidation 
chemotherapy will worsen neutropenia and thereby resulting in high 
attendant risk of infection and death.  
 Growth factors have shown to decrease morbidity in these 
patients. Pegylated growth factors are now being studied in this setting 
and its efficacy is compared with conventional GCSF.  
 But at present there are only very limited available literatures in 
both Western & Indian studies. 
 The application of pegylation technology has created a second 
generation molecule, pegfilgrastim, with significantly altered 
pharmacokinetic properties. The  pegylation markedly reduces renal 
clearance, leaving neutrophil-mediated clearance as the major route of 
elimination.(42) As a result, clearance of pegfilgrastim is decreased and 
serum concentrations are sustained throughout the duration of 
neutropenia.  
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 A single dose of pegfilgrastim was compared with daily filgrastim 
for supporting neutrophil recovery in patients treated for low-to-
intermediate risk acute myeloid leukemia: results from a randomized, 
double-blind, phase 2 trials. (49) To minimize inter-patient variability, 
they excluded high risk cytogenetic patients from study. 
 Recovery occurred after a median of 17.0 days for pegfilgrastim 
versus 16.5 days for filgrastim Therapeutic peg filgrastim serum 
concentrations were maintained throughout neutropenia.  Pegfilgrastim 
was well tolerated, with an adverse event profile similar to that of 
filgrastim. (49) There was also decrease in hospital stay in Peg filgrastim 
group of patients. 
 Compared with 1 pegfilgrastim injection, a median of 16 
filgrastim injections were required in induction and 13 in consolidation 
to ensure ANC recovery. (49)These results showed comparable or 
similar efficacy of peg GCSF in neutrophil recovery. 
 The German Cooperative group for AML used Dose-dense 
induction & further consolidation with sequential high-dose cytarabine 
and mitoxantone (S-HAM) and pegfilgrastim in AML (50).peg GCSF 
was given to all patients who was in morphological remission after 
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induction. Measurable pegfilgrastim plasma levels were observed up to 
day 14.  
 Pegfilgrastim clearance was significantly correlated with 
neutrophil recovery. Median time to neutrophil recovery was 12.7 days 
after injection.Due to this there was less neutropenia / toxicity and so 
deaths were also significantly reduced. (50) 
 In Another phase 2 Trial by Bossi & colleagues did multi centre 
randomized control trial comparing time of Neutrophil recovery, safety 
and efficacy of pegylated GCSF compared to conventional GCSF in 
patients undergoing AML induction & consolidation chemotherapy. (51) 
The results showed single agent peg GCSF had similar median time to 
recovery of ANC>500 compared to conventional GCSF. There was no 
difference in duration of severe neutropenia in both groups. Peg GCSF 
had a favourable toxicity profile and easy administration .Serum levels 
of pegylated growth factors were also maintained throughout period of 
neutropenia. (51)   
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Various studies on role of Peg GCSF in AML 
 
Study Phase Type Outcome Comments 
Sierra et al 
( N= 84) 
Induction+ 
consolidation 
RCT 
(peg vs 
GCSF) 
Equivalent 
ANC (17 vs 
16.5) 
Safety, no 
survival 
benefit 
German 
AML group 
 
Induction + 
consolidation 
RCT Equivalent 
effects 
Reduced 
toxic deaths 
 
 
Bossi et al 
(N= 84) 
Induction+ 
consolidation 
 
RCT 
Equivalent 
results 
Favourable 
toxicity of 
peg GCSF. 
Kunivayalil 
etal 
 (N=24  ) 
Consolidation  Comparative 
(Indian 
study) 
Faster ANC 
recovery & 
decreased 
hospital 
stay with 
Peg GCSF 
Favourable 
toxicity 
profile & 
equal febrile 
neutropenia 
 
Peg GCSF in AML Consolidation –Indian Data 
 Very sparse literature evidence is available from Indian scenario 
also for use of peg GCSF in AML consolidation. 
 A comparative study of 30 patients was done in Bangalore, of 
single-dose pegfilgrastim versus daily filgrastim in patients with acute 
myeloid leukemia consolidation. (52) In this study median time to 
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neutrophil recovery was 14 days for pegfilgrastim arm and 17 days for 
filgrastim arm. In the pegfilgrastim arm 12 (60%) episodes of febrile 
neutropenia occurred compared to 11 (55%) in filgrastim arm. The 
median duration of hospitalization was 15 days in pegfilgrastim arm and 
18 days in filgrastim arm. Safety profile and complete remission status 
did not differ between the two groups. (52) 
 
Need of Study: 
 Incidence of Acute leukemia is rising. AML patients are majority 
elderly. Major cause of mortality and morbidity has been infections .Peg 
GCSF has been found to have impact on available very limited literature.  
In a resource poor country like india even a single day decrease in 
neutropenia and hospital admission will have major impact on financial 
burden. Data on role of peg GCSF in AML patients are lacking in both 
western and Indian studies. Availability of generic versions of peg-
GCSF has considerably reduced the cost of therapy with peg GCSF. 
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MATERIALS & METHODS 
 
 
Study Design 
 Prospective Observational non interventional study  
Study Period  
 April 2012- December 2013  
Study population 
 All Acute myeloid leukemia patients (Adult & Pediatric) 
Undergoing Consolidation chemotherapy in Cancer institute 
(WIA),Adyar,Chennai 
Aim 
 To assess efficacy of Peg G CSF in Neutrophil recovery in 
patients of AML consolidation. 
 To compare efficacy of Peg GCSF patients with conventional 
GCSF subsets  
(Historical data from 2011-2012 from patients who had undergone AML 
consolidation treatment with conventional GCSF) 
Primary end point 
 Median duration of Neutrophil recovery in patients receiving Peg 
GCSF in AML consolidation. 
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Secondary end points 
 Incidence of Febrile Neutropenia during consolidation and usage 
of Antibiotics. 
 Side effects & Toxicity profile of peg GCSF in AML 
consolidation. 
 Median Duration of Hospital stay 
Materials & Methods  
Inclusion criteria 
1. All Adults & pediatric patients of AML undergoing consolidation 
chemotherapy with high /intermediate dose cytarabine. 
2. Bone marrow should be in remission before starting consolidation. 
3. Patients should provide informed consent. 
Exclusion criteria 
1. Acute Promyelocytic Leukemia (APML) . 
2.  Previous history of   anaphylaxis   to growth factors will be 
excluded. 
3. Combination of any other cytotoxic drug with Cytarabine if used 
in consolidation will be excluded from study. 
4. Any dose of cytarabine other than 3.0gm/m2 or 1.5gm/m2 will be 
excluded from study. 
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METHODS 
 
 
 All patients receive total 6 doses of cytosine arabinoside 
(1.5gm/3.0gm) on alternate day ,twice a day schedule .Peg GCSF will be 
given exactly 24 hrs after last dose of consolidation. Dose is 100mcg/kg 
for children & if weight >40kg standard dose of 6.0mg will be 
given.Route is sub cutaneous. Daily Haemogram will be done from next 
day of peg GCSF administration. Manual differential count was done 
and absolute Neutrophil count (ANC) will be calculated. Median day of 
neutrophil recovery was calculated.  
The following parameters were prospectively collected from the patient 
records: 
1. Median day of neutrophil recovery. Day 1 of ANC > 1000 for 3 
consecutive days was considered as the day of neutrophil 
recovery. Time to recovery was taken as 1 day for patients whose 
ANC remained >500 & didn’t have a dip in counts. 
2. Day 1 of Platelet count of >50,000 for 3 consecutive days was 
taken as platelet recovery. 
3. Incidence of febrile neutropenia, & its duration   
4. Duration of hospital stay  
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5. Organisms grown and antibiotic /antifungal used. 
6. Side effects and toxicity pofile of pegylated GCSF will be 
carefully assessed and will be graded as per NCI-CTCAEcriteria 
for all patients with Age >10 years (children <10 yr peg GCSF 
toxicity not assessed because same scale is not useful) 
7. Requirement of Blood (Packed Red cells) and blood Product 
(single donor/Random Donor) Platelet requirement during 
consolidation chemotherapy will be noted. 
 
 The data from these patients and its variables will be compared 
with the historical data of patients between April 2011-12 , who received 
conventional G-CSF. 
 
Statistical Analysis 
 Descriptive statistics were used for demographic details of the 
prospective and retrospective cohorts. Time based end points will be 
described as median values and compared between cohorts using the 
unpaired t test. Categorical variables will be assessed using the Fisher 
exact test. Statistical analysis will be done by SPSS software. 
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Calculation of ANC 
Absolute Neutrophil Count=   (% Neutrophils + %Bands)x WBC  
                                      100  
 The unit of ANC is cells per micro liter of blood. Normal ANC is 
>1500 cells/microliter.An ANC <500   increases the risk of 
infections.Grading of ANC is done as per NCI recommendation (Refer 
Appendix 2) 
Febrile Neutropenia 
 Febrile neutropenia (FN) was defined as a single oral temperature 
>38.3°C (101 F) or two consecutive readings of >38.0°C (100 F) for 1 
hour and an absolute neutrophil count <0.5 × 10
9
/l, or expected to fall 
below 0.5 × 10
9
/l. 
 Duration of febrile neutropenia was counted from 1
st
 day of 
temperature >100 F until first 2 consecutive days with temperature <38 
degree.  
 Blood Culture sensitivity were sent from both central & peripheral 
lines (5 ml each) at 1
st
 spike of fever before stating Antibiotics and each 
time when escalation of antibiotics was planned. 
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Antibiotic Policy in Febrile Neutropenia 
 Prophylactic antibiotic is not used as per our institution policy in 
AMl consolidation. 
 First-line antibiotics was Cefoperazone + Sulbactum with 
Amikacin. 2
nd
 line and third-line antibiotic used were 
Piperacillin+Tazobactum and carbapenem (Meropenem/Imipinem) 
respectively. 
 Teicoplanin was added for any patient with suspected/ proven 
gram positive infection or hypotension or mucositis. Antifungal use will 
be Amphotericin B/ Voriconazole as per clinical suspicion & further 
escalated if needed to Caspofungin. 
Adverse effect profile & Toxicity Grading  of  Peg GCSF 
 Classification & Grading according to NCI-CTCAE (National 
Cancer institute-Common Toxicity Criteria  (Kindly Refer Appendix  3) 
Blood/ Blood Product Tranfusion as per institution protocol during 
AML consolidation. 
 PRBC transfusion is given if Hemoglobin  <7.0gm/dl, symptom 
due to Anemia, or acute Blood loss. 
 Platelet transfusion is given for asymptomatic Thrombocytopenia 
with platelet count <20,000 or any signs of active bleeding manifestation 
irrespective of platelet count. 
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RESULTS 
 
 
Patient Characteristics 
 A total of 40 patients underwent consolidation therapy during this 
period. Altogether 116 Number of cycles of consolidation chemotherapy 
was administered. The baseline characteristics of the patients is given in 
table no.1&2 
Table No.1 
Variable N 
Total No. of patients studied 40 
Total No. of cycles consolidation 
studied 
116 
 
Table No.2                             Base line characteristics 
Variable N 
Age  
<15 yrs 20 
>/=15 yrs 20 
Median Age 22 yrs (Range 1-56  
yrs) 
Gender  
Male 25 
Females 15 
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Risk Category  
Good Risk 19 
Intermediate Risk 12 
Poor Risk 04 
Unknown status 05 
Induction received  
3 +7  38/40 
ADE 2/40 
 
 Age Distribution (Fig 1) 
 
 
 Gender  Distribution   (Fig 2) 
 
 
2020
Adult
Pediatric
25
15
Males
females
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 Risk Stratification (Fig 3) 
 
 
 t (8:21) was the most common Good Risk cytogenetics seen in 
about 13 patients. Inversion 16 was seen in remaining 6 patients. 
Normal cytogenetics was seen in 11/12 patients with 1 patient having 
trisomy 8. 
 All Poor risk cytogenetics was having complex abnormalty (>-3 
chromosome abnormalty). 
 4 patients in the study had no metaphysis available for 
karyotyping (Due to leucopenia/leukocytosis) and were stratified as 
unknown prognostic risk stratification group. 
 FLT3- ITD mutation status & NPM 1 was done in 19 patients.  
 Among these study patients most of them received induction with 
3+7 protocol. Only 2 patients received ADE induction.  
0
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Consolidation strategy among these total 116 cycles of chemotherapy is 
as described below.78 cycles was given HDAC(3.0gm/m2) and 38 cycle 
received IDAC(1.5gm/m2). 
 Table No.3 
Consolidation received  
HDAC (3.0gm/m2) 78 cycle 
IDAC   (1.5gm/m2) 38 cycle 
        
 (Fig 4) 
 
 
         
 Out of 116 cycles of consolidation therapy, peg GCSF was used in 
108 and conventional G CSF was used in 8. This was due to physician 
preference in 8 of these cycles. 
  
78
38
HDAC
IDAC
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Primary End point 
 The outcomes with respect to time variables are shown in table 
below. 
 Table No.4 
Median Duration of 
Neutrophil Recovery 
16.0 days        
        
Range (12-22 days) 
Duration of recovery in 
HDAC 
16.4 days Range (12-22 days) 
Duration of recovery in 
IDAC 
16.0 days Range (12-21 days) 
 
Secondary End Points 
Table No.5              
Average Duration of 
Grade 4 Neutropenia 
5.8 days Range (1-11 days) 
Median Duration of 
platelet recovery 
19.0 days 
 
Range (14-24 days) 
Median Duration of 
Hospital stay 
20.0 days Range (14-27 days) 
 In study the mean nadir WBC count was 300/cumm and mean 
nadir platelet count was 16,000/cumm . 
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Toxicity Profile of Peg GCSF  
 In these study 32/40 patients were assessed for toxicity profile(8 
patients were excluded as their age was <10 yrs). Total 92 cycles of 
pegylated GCSF was studied. Most common side effect noted in study 
was myalgia/Bone pains and fatigue.                      
1. Fatigue  
 Fatigue was experienced in 41 cycles (42%),but majority(38/41 
cycles) was mild grade1/2 fatigue. Only 3 cycles had grade 3 fatigue and 
no grade 4 fatigue was seen. Presence of Fatigue was more common by 
3
rd
 cycle of consolidation. (Out of 41 cycles having fatigue 25 was in 3
rd
 
cycle of consolidation) 
 
Grades of Fatigue 
 
Fatigue 
yes
No
0
10
20
30
Grades of Fatigue Grade 1 Grade 2 Grade 3 Grade 4
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2. Myalgia 
 Myalgia/Bone pain was reported in 36/92 cycle (38%). All were 
grade1/2. They were felt mainly in lower back, hip & calf muscle. There 
was no difference in distribution of myalgia as per cycle of 
consolidation. There were no reported Grade3/4 bone pains/myalgia in 
any age group. 
 
 
Grade of Myalgia 
 
 Further details of toxicity in study group are given in detail in 
below table 
Myalgia
yes
No
0
10
20
30
Grade of 
Myalgia
Grade 1
Grade 2
Grade 3/4
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Table No.6        Toxicity details in study Group 
 
Variable Present Grade 1 Grade 2 Grade 3 Grade 4 
Fatigue 
 
41/92   
(44%) 
23 
(56%) 
15 
(36%) 
3 0 
 
Myalgia 36/92 
(39%) 
22 
(66.1%) 
14 
(38.8%) 
0 0 
 
Bleeding 4 cycles - - - - 
Cellulitis 4 cycles - - - - 
Others 3 - - - - 
 
 Out of 4 bleeding – 1 was p/v bleed, 1 was gum bleed and other 2 
cases were Epistaxis. There was no life threatening bleeding 
manifestation in study group. 
 4 cycles in study population had cellulitis , 2 in psoas muscle and 
2 in thigh muscle. Blood C&S grew E.coli. It responded to Antibiotics. 
Other side effects include 1 pediatric patient in 3
rd
 cycle consolidation 
complaining of vague head ache, and 2 Adult patients found to have 
Grade 1 B/L Pitting pedal edema.  
 No patient developed anaphylaxis,flu-like syndrome, rash or   
hypersensitivity reactions.          
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Blood Product Requirement in Consolidation      
Table No.7 
Median PRBC 
requirement/cycle 
1.0/cycle Range (1-5/cycle) 
Median platelet 
requirement/cycle 
6.0 RDP/cycle Range (2-15/cycle) 
 
Febrile Neutropenia & Infective Complications Study Group 
Table No.8 
Total incidence of F N 102 cycles (88.8%) 
Incidence of FN in HDAC 89.5% 
Incidence of FN in IDAC 88.0% 
Most common days infective 
episodes 
Day 10-13 
Focus of Infection was found in 29 Patients (28.8%) and here are as 
follows 
 Pneumonia- 16 patients 
 Peri Anal region- 12 patients 
 Cellulitis – 4 patients 
 Colitis   -    1 patients   
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Blood Culture Positivity in AML Consolidation  
 Blood C& S Positivity in patients in study group- 17 cycles 
(17.9%) and the most common organism isolated are  
 Staphylococcal Aureus-total 8 /16 patients.  (MSSA- 7; MRSA–1) 
 Gram Negative Bacilli -4 patients 
 E.coli/ Acineto bacter-3 patient 
 Burkholderia species -2 patients    
Escalation to 3
rd
 line Antibiotics- 
 Escalation to 3
rd
 line Antibiotics during course of febrile 
neutopenia was done in 57 patients (55.5%). 
 No invasive Fungal/ Viral infection noted. 
 No Therapeutic Anti fungal/ Anti Viral used in study group. 
Mortality 
1 Mortality in study group- 
48 yr female, Good Risk AML on 3
rd
 HDAC consolidation developed 
febrile neutropenia. She developed B/L pneumonia +Gram negative 
septicemia & shock . She had progressive worsening of her respiratory 
status and expired on Day +18 AML consolidation. 
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Pediatric Sub group Analysis in Study population (Age <15 yrs) 
Table No.9 
Variable Number  
Total Pediatric patients 20  
Sex Males-13 
Females-07 
 
Median Age group 11 yrs (1-15 yrs )  
Cycles of consolidation 
studied 
  HDAC 
  IDAC 
60 
 
49 
11 
 
Conventional plain GCSF 
used 
1 cycle 
 
 
Dose of Pegylated GCSF 
used 
100mcg/ Kg  
Median Duration of  
Neutrophil Recovery 
16.0 days 
 
Range (12-22 days) 
Median Duration of  
Platelet Recovery 
19.0 days 
 
Range (14-27 days) 
Median Duration of  Gr.4  
Neutropenia 
6.0 days 
 
Range (2-11 days)  
Median duration  
Hospital stay 
20 days 
 
Range (16-26 days) 
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Febrile Neutropenia Incidence & Details in Pediatric Patients 
 51/60 cycle had fever (86.6%). Escalation to 3
rd
 line Antibiotics 
was done in 32 cycles (63.4 %). Focus of fever seen in 13 patients 
Blood Culture & Sensitivity 
13/51cycles had central line culture Positivity (25.2%). 
Most common Organism - MSSA (4 patients) 
     E.coli/ Acinetobacter 
     Burkholderia (2 patients)  
No Rash/Anaphylaxis or injection site pain noted in pediatric patients. 
No mortality seen in pediatric age group patients. 
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Historical Data on Plain GCSF in AML Consolidation (2011-12) 
Table 10 
Total No. of patients studied 29 
No. of cycles Analyzed 50 
Median Age  19 yrs (1-58yrs) 
Sex Males     21 
Females  8  
Consolidation Chemotherapy 
 
HDAC (3.0gm/m2)-39 
IDAC   (1.5gm/m2)-11 
Average  GCSF used/ cycle  12.0 Injections 
Median Duration Neutrophil 
Recovery 
17.0 days          Range (3-22 days) 
 
Median  Duration of Platelet 
recovery 
19.0 days          Range (16-24 days) 
Median Duration of Gr4 
Neutropenia 
7.0 days            Range (2-12 days) 
Median Hospital stay/ cycle 21.0 days          Range (16-26 days) 
Blood Product requirement PRBC - 1.4/ cycle 
RDP    - 4.0/cycle  
Febrile Neutropenia 44/50 cycles (88%) 
Escalation to 3
rd
 line Antibiotics 32/45 cycles (71.2%) 
 
  
48 
 
Comparison Data on Pegylated Gcsf Patient Subset with Historical 
Plain Gcsf Subset Study Population. 
Table 11 
Variable Pegylated GCSF Conventional GCSF 
Median Day of 
Neutrophil Recovery 
 16.0days 17.0 days 
Day of Platelet 
Recovery 
19.2 days 19.1 days 
Duration of Gr.4 
Neutropenia 
 5.8 days 7.2 days 
Hospital Stay 20 days 21.3 days 
Febrile Neutropenia  88.8% 88.0% 
Escalation to 3
rd
 line 
Antibiotics 
 45/78 (55.5%) 27/39 (71.1%) 
Blood Product 
Requirement 
PRBC 1.0 /cycle 
RDP   5.6/cycle 
PRBC 1.2/cycle 
RDP  4.0/cycle 
No. of injections 1 ~12 inj/cycle 
Mortality 1 3 
 
 Duration of neutrophil recovery & platelet recovery remained 
same in both subsets. There was reduction in duration of Grade 4 
neutropenia & hospital stay.Blood products were equal, except more 
platelet requirement in peg GCSF arm.The statistical significance of this 
comparitive findings were tested.  
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Statistical Analysis of Data on Patients Receiving High Dose Arac 
(3.0gm/m2) in Peg-Gcsf & Historical Plain Gcsf Subsets. 
(Total no. of cycles of HDAC – N= 78 in peg GCSF & N= 39 in Plain 
GCSF) 
Student t test Analysis 
Table No. 12 
Variable Peg GCSF 
Mean +- SD 
G CSF 
Mean +- SD 
   t P value 
Day of 
Neutrophil 
recovery 
16.3/2.9 
 
17.7/4.4 -1.593 0.076 
 (NS) 
Student t 
Duration of 
Grade4 
Neutropenia 
5.8/2.4 7.0/3.4 -2.90 0.003     (S) 
Student t 
Duration of 
platelet 
recovery 
 
19.3/3.4 19.7/4.0 -.481 0.63 
 (NS) 
Student t 
Platelet 
Transfusion 
 
6.0/ 3.6 5.0/2.6 .219 0.82 
 (NS) 
Student t 
Duration 
Hospital stay 
19.5/3.2 21.0/4.0 -2.33 0.009  
 (S)  
Student t 
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Chi Square Analysis 
Table No.13 
Variable Peg GCSF   
( N) 
G CSF  (N) Results 
Escalation to 3
rd
 line 
Antibiotics 
45/78 27/39 0.165 
 (NS) 
Ficher exact t 
test 
Mortality 1/40 2/29 0.257 
 (NS) 
Fischer exact 
t test 
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DISCUSSION 
 
 
 There are only very few western & Indian literature available on 
role of pegylated GCSF in AML patients. This prospective 
Observational study was done to evaluate their role in neutrophil 
recovery in AML Consolidation chemotherapy. It also evaluated the 
toxicity/side effect profile of Peg GCSF and compared the present data 
with historical data of patients treated in previous year (2011-12). 
 Our study has shown that single dose of pegylated GCSF has a 
median day neutrophil recovery of 16.0 days and is seen to have 
equivalent efficacy compared to multiple injections of conventional 
GCSF. It has shown to decrease the duration of grade 4 neutropenia . It 
also had reduced need to escalate to higher antibiotics as well as the 
hospital stay in these patients. It is also found to have a favourable 
toxicity profile. As per our knowledge this is the first study looking at 
efficacy of pegylated GCSF in children in AML consolidation. It was 
found to be equally effective in them.   
 The Median Age in study population was 22 years, (Range 1-56 
yrs) of patients. Males constituted 2/3
rd
 of patient population. Study by 
sierra et al included patients 18-74 yrs (49).study by Bosi etal also 
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included patient 18-70 yrs of age group (51). The available Indian 
literature by Kunivayalil et al included age group 18-60 yrs (52) and also 
had a male preponderance. 
 Risk stratification in our study showed 60% patients in good risk, 
followed by 30% intermediate risk. Only 5% population were poor risk. 
Study by Heil et al which looked at role of filgrastim, excluded poor risk 
patients (34). Sierra et al in his study on role of pegylated GCSF 
included Good or intermediate risk patients only, as it was expected to 
have delayed neutrophil recovery in High risk AML induction(49).The 
available Indian literature has not risk stratified patients with 
cytogenetics. 
 In our study the less representation of high risk group is because 
of institute management protocol. Most of the high risk patients and 
some intermediate risk patients in our institute directly go to Allogenic 
Bone marrow Transplant after Induction remission without receiving 
consolidation chemotherapy. 
 The primary end point in our study was median day of neutrophil 
recovery.The average day of neutrophil recovery in study group was 
16.0 days.This results are almost similar to western studies. 
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 Initial studies on plain GCSF has shown neutrophil recovery by 
18.0days in patients on high dose cytarabine(25).The literature on 
Pegylated GCSF by sierra et al showed  17.0days for   neutrophil 
recovery(34).The consolidation with HAM (High dose Arac 
+Mitoxantrone) by German cooperative AML group  had neutrophil 
recovery with median day of 13.0days(38).Bossi etal in his study had 
neutrophil recovery by 17.0days in peg GCSF arm (43). The available 
Indian literature, study by kunivayalil et al demonstrated neutrophil 
recovery by 14.0 days in Pegylated GCSF arm(37).  
 The definition of neutrophil recovery also varied among studies. 
The initial study by sierra etal and Bosi et al has taken ANC>500 for 2 
days as day of neutrophil recovery. But our study as well as study by 
kunivayalil et al has taken Day1 of ANC>1000 as day of neutrophil 
recovery. 
 Majority of our study population received High dose Ara C 
(3.0gm).When these data were compared to neutrophil recovery with 
intermittent dose Ara C (1.5gm) patients;   there was no major difference 
in period of recovery. It may be probably due to low number in 
intermittent dose group and selection of those patients. It requires further 
larger study to compare these data.   
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 The secondary endpoints included Platelet count recovery, 
incidence of febrile neutropenia and hospital stay.The median duration 
of platelet recovery was 19.0 days. The median duration of hospital stay 
was 20.0days. 
 Comparing to existing literature, platelet count recovery is around 
19 days (26-27) in conventional GCSF patients in AML consolidation. 
The existing literature has not studied platelet recovery endpoints in peg 
GCSF group. Various historical studies differ in taking threshhold of 
platelet recovery. Some use cutoff of 20,000 with no bleeding 
manifestation as recovery (especially post Bone marrow transplant), 
others use threshold of >50,000count. We have used the latter as 
definition of recovery in our study. This is of significance as 
thrombocytopenia is also common after administering peg GCSF. 
 The median duration of hospital stay was 19.0 days in study by 
sierra etal, and study from Bangalore, Kunivayalil etal had median 
hospital stay of 15 days in peg GCSF group. In our study patients were 
discharged by average 20.0 days from hospital. 
 Febrile neutropenia, incidence & Antibiotic use were studied 
extensively in our study. There was reported 88% incidence of fever. 
Study by sierra et al, 77% in peg gcsf arm developed febile neutropenia 
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during consolidation. Median duration of fever was 2 days; compared to 
4 days in our study. Bosi etal also had 80% incidence of febrile 
neutropenia. The study by kunivayalil et al had 60% incidence of fever. 
 Toxicity profile of patients with Peg GCSF was studied and 
graded as per NCI CTCAE criteria version 4.1. Most common side effect 
noted in study was fatigue and is seen in approximately 41% patients. 
But majority was grade 1or 2 &only 3% had grade 3 fatigue. 
Myalgia/Bone pains were seen in 38% patients. All were grade 1/2 and 
there were no grade 3/4 of these toxicties. There was no significant 
bleeding abnormality in our study group. Other toxicities were only 
rarely reported. 
 Sierra et al in his study had 26% adverse events in peg GCSF 
subgroup patients.  Fatigue was seen in 11% in his study population (But 
exact grading of fatigue is not done). Bosi etal had 18% fatigue in their 
study population. Bone pains / myalgia were seen in 7% of patients in 
study by sierra et al. Study of Peg GCSF in solid tumours had bone pains 
about 30% patients (42). Most common sites of pain in these studies 
were also back, lower limb calf and thigh muscles. The available Indian 
study also had favourable toxicity profile with peg GCSF.  No patient 
had Anaphylaxis reaction or severe life threatening toxicities in our 
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study group. These results were correlating with existing literature on 
pegylated GCSF in AML patients. 
 Statistical analysis with historical patients of conventional GCSF 
shows significant correlation for duration of severe neutropenia & 
average hospital stay. There was a trend to significance in duration of 
neutrophil recovery. The western studies had shown that peg GCSF had 
equivalent results to GCSF in helping neutrophil recovery & duration 
neutropenia. Available Indian study had shown efficacy of Peg GCSF 
over conventional growth factors in hastening neutrophil recovery & 
there by hospital stay. Other variables including febrile neutropenia, 
blood product requirement, and platelet recovery had no statistical 
significance which is similar to existing literature. 
 There was 1mortality in Peg GCSF group in our study.  The cause 
of death was infective with B/L pneumonia with septic shock. Patient did 
not recover counts and succumbed to illness by Day 18 of third cycle 
chemotherapy. Earlier study by sierra & Bosi et al also had 1mortality in 
Peg GCSF study group which was also due to infection. There was no 
mention on incidence of mortality in previous Indian study on Pegylated 
GCSF. 
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Comparison of Available literature & outcome of peg GCSF with 
present study   
Variable Sierra et al Bosi et al Kunivayalil 
et al 
Present 
study 
Age 18-74 yrs 18-70 yrs 18-60 yrs 1-56 yrs 
Phase of 
AML 
studied 
Induction+ 
consolidation 
Induction + 
consolidation 
Consolidation Consolidatio
n 
Risk Good/Intermed
iate Risk only 
Good/ 
Intermediate 
Risk only 
Not stratified All Risk 
group 
patients. 
Avg. Day 
of 
neutrophil 
recovery 
17.0days (peg) 
       V 
16.5 days 
16.0days (peg) 
        V 
 16.5 days 
15.0day (peg) 
       V  
18.0 days 
16.0day 
(peg) 
      V  
17.0 days 
Febrile 
neutropenia 
77% 80% 60% 88% 
Duration of 
hospital 
stay 
19.0days Not assessed 15.0days 20.0 days 
Comments Single dose 
Peg GCSF 
equivalent to 
GCSF 
Single dose 
Peg GCSF 
equivalent to 
GCSF 
Single dose 
Peg GCSF 
better than 
GCSF  
Single dose 
Peg GCSF 
equivalent 
to GCSF 
 
 As per our knowledge this is the first study on role of pegylated 
GCSF in AML consolidation in pediatric age group. Dose of peg GCSF 
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used by us was 100mcg/kg, which was same used by other groups in 
children for neutrophil recovery (45).The median day of neutrophil and 
platelet recovery was same as adult population. There was more 
favourable toxicity profile in children. Bone pain/myalgia was 
commonest toxicity. There was no anaphylaxis/life threatening toxicity 
in children. These results are comparable to available scanty evidence of 
role of Peg GCSF in children. 
 Our study has shown that single dose of pegylated GCSF may be 
of equivalent efficacy as compared to multiple daily GCSF injection in 
treating patients of AML consolidation. Duration of severe neutropenia 
and hospital stay was less in peg gcsf group in our study, which was 
statistically significant. This will have a major impact on decreasing cost 
burden especially on resource limited developing countries. Peg GCSF 
also limits multiple injections to the patients. 
 
 
 
 
  
59 
 
 
 
CONCLUSION 
 
 
1. Single dose of Pegylated GCSF injection is equivalent to multiple 
conventional GCSF injections in hastening neutrophil recovery in 
patients of AML undergoing consolidation chemotherapy. 
2. Peg GCSF has shown to decrease the median duration of grade 4 
neutropenia, and also lower need for escalation to 3
rd
 line 
antibiotics in these patients during febrile episode. 
3. Peg GCSF has shown to decrease the duration of hospital stay in 
these patients. 
4. Peg GCSF has a favourable toxicity profile with no life 
threatening side effects. 
5. Peg GCSF is well tolerated in pediatric age group also with equal 
efficacy and tolerable side effect profile. 
6. Single dose Peg GCSF limits multiple injections to these patients. 
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LIMITATIONS OF STUDY 
 
 
1. Small number of study population, requires larger number for 
accurate assessment of efficacy. 
2. Not a Randomized study, data was compared with historical 
cohorts. 
3. Follow up is short, needs long term follow up. 
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Appendix 1 
  Institute AML Management protocol (in Fit patients) 
    Good Risk -          3 cycle consolidation Ara-c 
3+7 induction   Intermediate Risk- 3 cycle Ara C or  Allo BMT 
     High Risk-      Allogenic BMT or Arac 3 cycle 
 Induction     Consolidation  
 
Appendix 2 
 ANC criteria for grading Neutropenia 
NCI Risk Category ANC 
0 Within normal limits 
1 ≥1500 - <2000/mm³ 
2 ≥1000 - <1500/mm³ 
3 ≥500 - <1000/mm³ 
4 < 500/mm³ 
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Appendix 3-  (NCI -CTCAE Version 4.1) 
 Adverse effect profile & Toxicity Grading of Peg GCSF    
Variable Grade 1 Grade 2 Grade 3 Grade 4 
Fatigue Increased 
fatigue in 
relation to 
the baseline , 
but without 
interfering 
with normal 
activity 
Moderate 
fatigue  
 Difficulty in 
carrying out 
Instrumental 
activity of 
daily living. 
ADL- I 
Severe fatigue 
  Difficulty in 
carrying out 
self care 
activity of daily 
living. 
ADL-SC 
Bed bound 
or severe 
disability. 
LTC 
Myalgia Mild pain 
without 
interfering 
normal 
activities 
Moderate 
pain 
Limiting 
instrumental 
activity of 
daily living 
ADL-I 
Severe pain  
Limiting 
acitivity of self 
care 
ADL-S 
Bed bound 
or severe 
disability 
Vomiting 1-2 episodes 
in 24 hrs 
3-5 episodes 
in 24 hrs 
 >6 episodes in 
24 hrs or any 
hospitalization 
indicated 
Life 
threatening 
toxicity 
Hemoglobin 
 
 
<10.0 or 
<LLN 
8.0-9.9 6.5-7.9 or 
Transfusion 
indicated 
Life 
threatening 
toxicity 
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ABBREVIATIONS 
 
 
AML  - Acute Myeloid Leukemia 
G CSF - Growth Colony Stimulating Factors 
Peg GCSF - Pegylated form of GCSF 
DNR  - Daunorubicin 
Ara C  - Cytarabine Arabinoside 
HDAC - High Dose Ara C 
IDAC  - Intermittent Dose Ara C 
IFI   – Invasive Fungal Infection 
PRC  - Packed Red cells 
RDP  - Random Donor platelets 
SDP  - Single Donor Platelets 
FFP  - Fresh Frozen Plasma 
ANC  - Absolute Neutrophil Count 
ABX  - Antibioics 
RFT  - Renal Function test 
F.N  - Febrile Neutropenia 
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PATIENT INFORMED CONSENT 
 
 
 I      have been informed by Dr.   
  that I am suffering from blood cancer.  The treatment will include chemotherapy 
which includes the use of anti caner drugs as injections and antibiotics, antifungals, antiviral 
drugs, as prophylactic and therapeutic purposes.  Patient will require central venous line and 
intensive care monitoring. 
 These medicines are associated with toxicities, some of which may occur 
immediately while others can occur at a later date.  The common and important immediate 
side effects of treatment include nausea and vomiting, diarrhea, hair loss, low counts and 
ulcers in mouth.  Patients can have life threatening infection or bleeding complications 
which can occur during any phase of chemotherapy, but more common during the initial 
phase of chemotherapy. Rarely patients may develop allergic reaction to drugs causing low 
BP, sudden cardiac failure and chest discomfort with breathing difficulty during 
hospitalization.  Growth factor support may be needed to improve low counts due to 
chemotherapy administration.  Very rarely the infused drugs may leak through the veins and 
cause skin ulceration which may require surgical correction.  Complications of antibiotics, 
antifungal drugs and antiviral drugs informed.   
 Some important late complications like infertility and difficult child bearing and 
cardiac dysfuncition are potentially possible.  Second cancers have also been reported rarely 
after treatment of primary cancer.  I understand that blood transfusion may be required 
during the course of treatment which may be associated with immediate complications like 
fever, transfusion reactions and rarely later, liver infection and jaundice. 
 Response to treatment is variable and depends on the risk stratification of cancer and 
other related factors pertaining to the disease and the patient.  Once there is good response to 
initial treatment, patient will require further treatment in the form of additional 
chemotherapy or stem cell transplant.  There is chance of cancer coming back at any phase 
of treatment or during follow up. 
 After completion of treatment the patient may be required to be followed up 
regularly.  The financial implications of my therapy has been explained to me.  The nature of 
my disease has been explained to me by the doctors, in the language I clearly understand.  
After understanding all the facts, I am willing for the above mentioned treatment.   
 
WITNESS     DOCTOR    PATIENT 
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                                                     PROFORMA  
 
 Name :                                     Sex :  Age :           UHID:  
Ward: 
Consent obtained : Y/N  
Final Diagnosis : AML  ( Y/N)  Subtype(M1/M2/M3/M4/M5/M6) 
Cytogenetics :  Good / Intermediate / poor    ( Mention -                                      ) 
Induction :  ADE  /  3+7      No.of  induction cycles : 1 / 2 
Marrow at end of induction :  CR / Not in CR 
Date of Starting Consolidation :    PS  -    
Date of Administration Peg Gcsf :   Dose Of Peg Gcsf: 
Duration of gr 4  Neutropenia :     Date of Neutrophil  
recovery :   
Date of Discharge :     Duration Hospital Stay : 
Date of platelet recovery:     Plain GCSF used :  (Y/N) ( 
Days/ reason            )   
Consolidation Chemotherapy :       HIDAC  /  IDAC / Others           
Cycle of consolidation : 1 / 2/ 3     Dose of Arac :        /m2 
Complications in consolidation :       
 Fever  :        Y/N          Duration:     Blood Culture +ve – Y/N (----
- )   Focus-  
 Gen. Fatigue  :     Y/N       Grade:  1/2/3/4                            
 Days : 
 Myalgia :      Y/N                   Grade:1/2/3/4      
Site :  
Bleeding Manifestation :     Y/N  Site :   
Cough / pneumonitis  : 
 Abdominal symptoms:                                                                  
Others :  
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Antibiotic used  :     Cefoperazone / Sulbactum  Y/N      Days : 
     Piperacillin + Tazobactum     Y/N               Days : 
     Meropenem/ Imipinem        Y/N                Days: 
    Teicoplanin          Y/N   Days 
                                                        Amikacin            Y/N               Days 
Antifungal  :                Ampho B /  Voriconazole / Caspofungin /fluco     
Days – 
Antivirals :   Y/N 
Blood products Used :                    PRC -    RDP -  SDP-  FFP- 
 Day1 Day7 Day21 
RFT    
LFT    
PROTIEN/ALBUMIN    
WEIGHT    
OTHERS    
 
Haemogram Values:       (From Day of administration of peg GCSF) 
Day            
HB            
TC            
Man DC            
Plt.count            
ANC            
 
Mortality  -      Y/N                   Day  -     Cause of death –  
Out of study  - Y/N                 Reason -      
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